Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year


Summary for Tradename: MICARDIS HCT

Suppliers: see list4
patent expirations by year for

Pharmacology for Tradename: MICARDIS HCT

Clinical Trials for: MICARDIS HCT

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
Status: Completed Condition: Hypertension

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
Status: Completed Condition: Hypertension; Cardiovascular Diseases

Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
Status: Completed Condition: Hypertension

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
Status: Completed Condition: Hypertension

Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
Status: Completed Condition: Hypertension

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)
Status: Completed Condition: Hypertension

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
Status: Completed Condition: Hypertension

Telmisartan, Amlodipine and Flow Mediated Dilation
Status: Active, not recruiting Condition: Hypertension

Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study
Status: Completed Condition: Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
hydrochlorothiazide; telmisartan
TABLET;ORAL021162Apr 19, 2004RXYes5,591,762<disabled>YY<disabled>
Boehringer Ingelheim
hydrochlorothiazide; telmisartan
TABLET;ORAL021162Nov 17, 2000RXNo5,591,762<disabled>YY<disabled>
Boehringer Ingelheim
hydrochlorothiazide; telmisartan
TABLET;ORAL021162Nov 17, 2000RXNo6,358,986<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MICARDIS HCT

Drugname Dosage Strength RLD Submissiondate
telmisartan and hydrochlorothiazideTablets80 mg/25 mgMicardis HCT2/27/2009
telmisartan and hydrochlorothiazideTablets80 mg/12.5 mg and 40 mg/12.5 mgMicardis HCT12/31/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology